August 9, 2024 12:33 PM EDT

Alfasigma's PBC treatment Ocaliva to face an FDA adcomm in September

Max Bayer

Pharma Reporter

Italian pharma Alfasigma will face an FDA advisory committee next month to discuss the full approval of its rare liver disease treatment Ocaliva, a drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alfasigma's PBC treatment Ocaliva to face an FDA adcomm in September

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Breaking down silos with a new quantitative approach to drug development

Al­fasig­ma's PBC treat­ment Ocali­va to face an FDA ad­comm in Sep­tem­ber

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Alfasigma's PBC treatment Ocaliva to face an FDA adcomm in September